Hypoferremic State in Overweight and Obese Children
D Siyaram1, P Bhatia2, D Dayal1
1Department of Pediatrics, Advanced Pediatrics Centre, PGIMER, Chandigarh, India.
Indian Pediatrics
|February 4, 2018
Summary
Children with high body mass index (BMI) face significant risks of iron deficiency. This study found a high prevalence of anemia and low iron levels in overweight and obese children, highlighting a critical public health concern.
Area of Science:
- Pediatrics
- Nutritional Science
- Hematology
Background:
- High body mass index (BMI) in children is increasingly linked to various health issues.
- Iron deficiency is a common nutritional deficiency with significant health implications.
- Overweight and obesity may influence iron status in pediatric populations.
Purpose of the Study:
- To investigate the prevalence of iron deficiency in children with overweight or obesity.
- To assess the relationship between high BMI and iron status markers in children.
Main Methods:
- Screening of 71 children diagnosed with overweight or obesity for iron deficiency.
- Measurement of key iron status indicators including ferritin and plasma soluble transferrin receptor (sTrfR).
- Calculation of mean BMI, ferritin, and sTrfR levels.
Main Results:
- The mean BMI of the study group was 26.1 kg/m2.
- Mean ferritin levels were 41.9 µg/L and mean sTrfR levels were 0.375 mg/L.
- A significant proportion of children, 28%, had anemia, and 62% exhibited a hypoferraemic state.
Conclusions:
- Children with overweight or obesity are at a high risk for iron deficiency.
- The findings underscore the need for routine iron status screening in pediatric populations with high BMI.
- Early detection and intervention are crucial to prevent long-term health consequences associated with iron deficiency in this demographic.
Related Concept Videos
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Drug Dosing: Infants and Children
335
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
335
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
300
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
300
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
197
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Pedigree Analysis
89.9K
Overview
89.9K


